Skip to content

Research at St Andrews

In vitro assay development and HTS of small molecule human ABAD/17β-HSD10 inhibitors as therapeutics in Alzheimer’s Disease

Research output: Contribution to journalArticle

Author(s)

Laura Aitken, Gemma Baillie, Andrew Pannifer, Angus Morrison, Philip S. Jones, Terry K. Smith, Stuart P. McElroy, Frank J. Gunn-Moore

School/Research organisations

Abstract

A major hallmark of Alzheimer’s disease (AD) is the formation of neurotoxic aggregates composed of the amyloid-β peptide (Aβ). Aβ has been recognized to interact with numerous proteins, resulting in pathological changes to the metabolism of patients with AD. One such mitochondrial metabolic enzyme is amyloid-binding alcohol dehydrogenase (ABAD), where altered enzyme function caused by the Aβ-ABAD interaction is known to cause mitochondrial distress and cytotoxic effects, providing a feasible therapeutic target for AD drug development. Here we have established a high-throughput screening platform for the identification of modulators to the ABAD enzyme. A pilot screen with a total of 6759 compounds from the NIH Clinical Collections (NCC) and SelleckChem libraries and a selection of compounds from the BioAscent diversity collection have allowed validation and robustness to be optimized. The pilot screen revealed 16 potential inhibitors in the low µM range against ABAD with favorable physicochemical properties for blood-brain barrier penetration.
Close

Details

Original languageEnglish
Pages (from-to)676-685
Number of pages11
JournalSLAS Discovery
Volume22
Issue number6
Early online date17 Mar 2017
DOIs
StatePublished - Jul 2017

    Research areas

  • Enzyme assays or enzyme kinetics, Neurodegenerative diseases, Pharmacology: ligand binding, Receptor binding, Ultra-high throughput screening

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. 6-benzothiazolyl ureas, thioureas and guanidines are potent inhibitors of ABAD/17β-HSD10 and potential drugs for Alzheimer's disease treatment: design, synthesis and in vitro evaluation

    Benek, O., Hroch, L., Aitken, L., Dolezal, R., Guest, P., Benkova, M., Soukup, O., Musil, K., Hughes, R., Kuca, K., Smith, T. K., Gunn-Moore, F. & Musilek, K. Jun 2017 In : Medicinal Chemistry. 13, 4, p. 345-358 14 p.

    Research output: Contribution to journalArticle

  2. Synthesis and evaluation of frentizole-based indolyl thiourea analogues as MAO/ABAD inhibitors for Alzheimer’s disease treatment

    Hroch, L., Guest, P., Benek, O., Soukup, O., Janockova, J., Dolezal, R., Kuca, K., Aitken, L., Smith, T. K., Gunn-Moore, F., Zala, D., Ramsay, R. R. & Musilek, K. 1 Feb 2017 In : Bioorganic & Medicinal Chemistry. 25, 3, p. 1143-1152 10 p.

    Research output: Contribution to journalArticle

  3. Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer’s disease treatment

    Hroch, L., Benek, O., Guest, P., Aitken, L., Soukup, O., Janockova, J., Musil, K., Dohnal, V., Dolezal, R., Kuca, K., Smith, T. K., Gunn-Moore, F. J. & Musilek, K. 1 Aug 2016 In : Bioorganic and Medicinal Chemistry Letters. 26, 15, p. 3675-3678 4 p.

    Research output: Contribution to journalLetter

  4. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders

    Benek, O., Hroch, L., Aitken, L., Gunn-Moore, F., Vinklarova, L., Kuca, K., Perez, D. I., Perez, C., Martinez, A., Fisar, Z. & Musilek, K. 2018 In : Journal of Enzyme Inhibition and Medicinal Chemistry. 33, 1, p. 665-670 6 p.

    Research output: Contribution to journalArticle

  5. Morphology-specific inhibition of β-amyloid aggregates by 17β-hydroxysteroid dehydrogenase type 10

    Aitken, L., Quinn, S. D., Perez-Gonzalez, D. C., Samuel, I. D. W., Penedo-Esteiro, J. C. & Gunn-Moore, F. J. 2 Jun 2016 In : ChemBioChem. 17, 11, p. 1029-1037

    Research output: Contribution to journalArticle

ID: 249348383